Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Amylase alpha pseudogene 1 (AMYP1, also known as AMY2P) is a member of the amylase gene family in humans and is classified as a pseudogene, meaning it resembles other amylase genes but does not encode a functional enzyme[6][7]. Pseudogenes like AMYP1 arise from gene duplication or retrotransposition events but typically have accumulated mutations that prevent them from producing a functional protein. While the functional amylase genes (such as AMY1A, AMY1B, AMY2A) encode active enzymes involved in starch and glycogen digestion, AMYP1 contains sequence features typical of the alpha-amylase genes but is not transcribed or translated into a functional product[6][7]. Pseudogenes can sometimes have regulatory or evolutionary significance, but AMYP1 is not considered a protein, does not have a role in human physiology or disease, and has no relevance as a therapeutic target. Summary: AMYP1 (amylase alpha pseudogene 1) is a non-functional gene related to amylase, with no protein product or role as a drug target[6][7].
None - As above, there are no known mechanisms of action, since AMYP1 does not produce a functional protein
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Amylase alpha pseudogene 1 (AMYP1).